Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer

Autor: Cunningham, D. ^*, Sirohi, B., Pluzanska, A., Utracka-Hutka, B., Zaluski, J., Glynne-Jones, R., Koralewski, P., Bridgewater, J., Mainwaring, P., Wasan, H., Wang, J.-Y., Szczylik, C., Clingan, P., Chan, R.T.T., Tabah-Fisch, I., Cassidy, J.

Publikováno v: In Annals of Oncology February 2009 20(2):244-250

Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen

Autor: Martín, M. ^*, Lluch, A., Seguí, M.A., Ruiz, A., Ramos, M., Adrover, E., Rodríguez-Lescure, Á., Grosse, R., Calvo, L., Fernandez-Chacón, C., Roset, M., Antón, A., Isla, D., del Prado, P. Martínez, Iglesias, L., Zaluski, J., Arcusa, A., López-Vega, J.M., Muñoz, M., Mel, J.R.

Publikováno v: In Annals of Oncology August 2006 17(8):1205-1212

Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial

Autor: Scheithauer, W. ^*, McKendrick, J., Begbie, S., Borner, M., Burns, W.I., Burris, H.A., Cassidy, J., Jodrell, D., Koralewski, P., Levine, E.L., Marschner, N., Maroun, J., Garcia-Alfonso, P., Tujakowski, J., Van Hazel, G., Wong, A., Zaluski, J., Twelves, C.

Publikováno v: In Annals of Oncology December 2003 14(12):1735-1743

Adjuvant Docetaxel for High-Risk, Node-Negative Breast Cancer

Autor: Martin M, Segui M, Anton A, Ruiz A, Ramos M, Adrover E, Aranda I, Rodriguez-Lescure A, Grosse R, Calvo L, Barnadas A, Isla D, del Prado P, Borrego M, Zaluski J, Arcusa A, Munoz M, Vega J, Mel J, Munarriz B, Llorca C, Jara C, Alba E, Florian J, Li J, Garcia-Asenjo J, Saez A, Rios M, Almenar S, Peiro G, Lluch A, GEICAM 9805 Investigators

Publikováno v: NEW ENGLAND JOURNAL OF MEDICINE
r-FISABIO. Repositorio Institucional de Producción Científica
instname
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)

Background: A regimen of docetaxel, doxorubicin, and cyclophosphamide (TAC) is superior to a regimen of fluorouracil, doxorubicin, and cyclophosphamide (FAC) when used as adjuvant therapy in women with node-positive breast cancer. The value of taxane

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f417b475b3056c58ea363d7f178c0714
https://fundanet.fisabio.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=7013

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.